|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||10.67 / 19.98|
Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Single-agent, anti-tumor activity observed in 7/18 evaluable patients with solid tumors, including one unconfirmed partial response per RECIST 1.1
Data from Phase 1 dose-escalation trial of NKTR-214 to be presented by lead clinical investigators
Five data presentations will showcase Nektar's immuno-oncology candidates, NKTR-214 and NKTR-255
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
Biotech stocks dominate our list of top charts today. Here are four to watch.
The big issue is if the market can build on Friday's jobs good news.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Computer programming has found that buying bad-news dips is a consistent winner.
Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate
John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar